Comparative Effect of Divided Doses of Adult Solid and Liquid Oral Formulations of Antiepileptic Drugs in the Management of Pediatric Epilepsy
- 1,
- 1,
- 1,
- 1*
- 1Departments of Pharmacology and Pediatrics, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.
Published in Journal of Pharmacology and Pharmacotherapeutics
Correspondence: Batmanabane Gitanjali
Departments of Pharmacology and Pediatrics, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.
Email: gitabatman@gmail.com
Copyright: © 2017 The Author(s). This is an open access article.
Published: Jan 1, 2017, Received: Jan 19, 2017, Accepted: Mar 31, 2017
Abstract
Objective: To compare the differences in the efficacy and safety of the commonly prescribed AEDs in the management of epilepsy in children when using divided doses of adult solid oral formulations (DDSF) with the liquid oral formulations (LFs). Materials and Methods: Patients who had one or more seizures per month and prescribed with DDSF were recruited. Initially the patients were continued on DDSF for 4 months following which they were switched over to LF for the subsequent 4 months. Seizure frequencies and adverse drug effects (ADRs) were recorded every month for 8 months and plasma AED levels were estimated at the end of 4th and 8th months. Results: A total of 200 patients completed the study protocol. The median seizure frequencies per month with DDSF and LF were: partial seizures (20.5, 9.0; P < 0.001), generalized tonic‑clonic seizures (6.5, 2.0; P < 0.001), myoclonic seizures (58.5, 29.0; P < 0.001). Mean plasma drug levels ± SD (μg/ml) with DDSF and LF were: sodium valproate (48.2 ± 13.7, 69.1 ± 16.3; P < 0.001), phenytoin sodium (5.0 ± 2.4, 12.8 ± 3.8; P < 0.001), carbamazepine (4.5 ± 2.0, 11.5 ± 4.8; P < 0.001) and phenobarbitone (14.1 ± 5.2, 25.4 ± 12.3, P < 0.001). The incidence of treatment emergent ADRs was poor scholastic performance (25.5%), behavioral problems and dizziness/sedation (21.0%), somnolence/sleep disorders (19.5%). Conclusion: Patients treated with LF had better seizure control and optimal therapeutic drug levels and less adverse effects when compared to DDSF.
Keywords
Subject
Recommended articles
- L-asparaginase in the treatment of patients with acute lymphoblastic leukemia
Rachel A. Egler, Sanjay P. Ahuja, Yousif Matloub · Journal of Pharmacology and Pharmacotherapeutics
- Folic acid supplementation on homocysteine levels in children taking antiepileptic drugs: A randomized controlled trial
Mathummal Cherumanalil Jeeja, Thayyil Jayakrishnan, Puthiya Veettil Narayanan · Journal of Pharmacology and Pharmacotherapeutics
- A possible case of natalizumab-dependent suicide attempt: A brief review about drugs and suicide
Laura Mumoli, Miriam Ciriaco, Antonio Gambardella · Journal of Pharmacology and Pharmacotherapeutics
Readers Also Viewed
Pharmacogenomics Meets Generative AI: Transforming Clinical Trial Design with Large Language Models
Annisa Fatharani, Ali Alsayegh
Jan 1, 2026
Clinical Outcomes and Management of Post-varicocelectomy on Male Fertility: A Comprehensive Review
Mohammad Akbar Hossain
Jan 1, 2026
Knowledge, Attitude, and Practice on Digital Eye Strain Among Healthcare Students at a Private University in Northern Peninsular Malaysia
Lim Chin Hung, Subramani Parasuraman, Sam Aaseer Thamby
Jan 1, 2026